Holen Sie sich die Stockscreener-App
20.76
1.14%
-0.24
Vorhandelsmarkt:
20.76
Schlusskurs vom Vortag:
$21.00
Offen:
$20.74
24-Stunden-Volumen:
1.16M
Relative Volume:
0.80
Marktkapitalisierung:
$1.84B
Einnahmen:
Nettoeinkommen (Verlust:
$-151.78M
KGV:
-10.08
EPS:
-2.0595
Netto-Cashflow:
$-136.42M
1W Leistung:
-7.24%
1M Leistung:
-28.19%
6M Leistung:
-31.76%
1J Leistung:
-52.11%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$20.41
$23.68
52-Wochen-Spanne:
$20.41
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
20.76 | 1.84B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Eingeleitet | UBS | Neutral |
| 2026-04-27 | Eingeleitet | TD Cowen | Buy |
| 2025-06-11 | Eingeleitet | Jefferies | Hold |
| 2024-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 - GlobeNewswire Inc.
After a CEO share sale, 528,621 shares remain with Mineralys Therapeutics (MLYS) chief. - Stock Titan
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 - GlobeNewswire Inc.
A 75,000-share sale is proposed by a Mineralys (MLYS) officer and director. - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com South Africa
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com South Africa
Mineralys Therapeutics director sells $3 million in shares - Investing.com
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Nigeria
A fund sold Mineralys (MLYS) shares and still holds more than 7.8 million. - Stock Titan
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Mineralys Therapeutics Inc For: 22 September - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com
Fund may sell Mineralys (NASDAQ: MLYS) shares; filing shows the size - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mineralys Therapeutics (MLYS) officer lines up new stock option sale - stocktitan.net
A new employee gets Mineralys stock awards covering 14,880 and 11,160 shares - Stock Titan
Mineralys Therapeutics (MLYS) CCO sells 7,438 shares in pre-set plan - Stock Titan
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics director Karydas sells $85,740 in stock - Investing.com
Mineralys Therapeutics (MLYS) director sells shares under preset plan - stocktitan.net
Mineralys Therapeutics (NASDAQ: MLYS) executive plans new stock option sale after recent $388K trade - stocktitan.net
Mineralys (NASDAQ: MLYS) officer to sell 3,000 shares via options - stocktitan.net
Mineralys (MLYS) officer to sell 7,709 shares - stocktitan.net
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Mineralys Therapeutics grants inducement equity awards covering 52,080 shares to new hires - Bitget
Mineralys at Wells Fargo conference: lorundrostat launch takes shape By Investing.com - Investing.com Canada
MLYS: Lorundrostat nears approval with strong data, broad market prep, and a focus on parity access - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) insider to sell 2,171 shares via cashless option exercise - Stock Titan
Two new hires get four-year stock awards from Mineralys - stocktitan.net
Mineralys Therapeutics Market Sentiment - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Mineralys Therapeutics upgraded to Buy ahead of lorundrostat FDA approval and strong market launch. - Pluang
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS) - Seeking Alpha
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Wells Fargo healthcare conference puts Mineralys management on Sept. 9 agenda - Stock Titan
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com UK
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan - stocktitan.net
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares - Investing.com
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - stocktitan.net
Mineralys Plunges As Costly Royalty Deal Shocks Wall Street - TipRanks
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management - BioBuzz
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mineralys Therapeutics Inc-Aktie (MLYS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Congleton Jon | Chief Executive Officer |
Sep 30 '26 |
Sale |
25.46 |
75,000 |
1,909,665 |
528,621 |
| Congleton Jon | Officer |
Sep 30 '26 |
Proposed Sale |
25.46 |
75,000 |
1,909,662 |
0 |
| Slingsby Brian Taylor | Director |
Sep 22 '26 |
Sale |
28.81 |
104,320 |
3,005,303 |
7,805,718 |
| CATALYS PACIFIC FUND LP | Director |
Sep 22 '26 |
Proposed Sale |
28.81 |
104,320 |
3,005,303 |
0 |
| Warren Eric | Officer |
Sep 21 '26 |
Proposed Sale |
28.12 |
7,438 |
209,135 |
0 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Option Exercise |
13.24 |
7,438 |
98,479 |
45,838 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Sale |
28.12 |
7,438 |
209,136 |
38,400 |
| Rodman David Malcom | Officer |
Sep 17 '26 |
Proposed Sale |
27.95 |
417 |
11,655 |
0 |
| Karydas Daphne | Officer |
Sep 15 '26 |
Proposed Sale |
28.58 |
3,000 |
85,740 |
0 |
| Karydas Daphne | Director |
Sep 15 '26 |
Option Exercise |
12.02 |
3,000 |
36,060 |
9,200 |
2.52%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):